JIP
TEVA icon

Jaffetilchin Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Jaffetilchin Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-472
Closed -$8.51K – 1210
2024
Q3 		$8.51K Buy
+472
New +$8.26K ﹤0.01% 934
2023
Q4 		– Sell
-23,578
Closed -$240K – 375
2023
Q3 		$240K Buy
+23,578
New +$220K 0.03% 298
2021
Q4 		– Sell
-14,855
Closed -$145K – 384
2021
Q3 		$145K Sell
14,855
-23,175
-61% -$217K 0.02% 350
2021
Q2 		$371K Buy
38,030
+21,665
+132% +$229K 0.03% 301
2021
Q1 		$189K Sell
16,365
-4,600
-22% -$52.7K 0.02% 344
2020
Q4 		$202K Buy
+20,965
New +$201K 0.03% 262
2018
Q3 		– Sell
-47,527
Closed -$1.16M – 337
2018
Q2 		$1.16M Buy
+47,527
New +$969K 0.26% 71
2014
Q3 		– Sell
-9,532
Closed -$500K – 241
2014
Q2 		$500K Buy
+9,532
New +$487K 0.18% 93

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Jaffetilchin Investment Partners's TEVA Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 472 shares — an estimated $8.51K sold.

Jaffetilchin Investment Partners first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $1.16M in Q2 2018. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 472 Teva Pharmaceuticals shares in Q4 2024, an estimated $8.51K.
  • Jaffetilchin Investment Partners first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • Jaffetilchin Investment Partners's Teva Pharmaceuticals position peaked at $1.16M in Q2 2018.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.